Pierre Gholam, MD
Gastroenterology · Cleveland, OHNPI 1477579647
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,196,450 of the $1,606,241 with a category attached, or 74.5%. It is spread thinly across 35 manufacturers, the largest accounting for just 16.5%. Among gastroenterology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,798 payments — averaging $893.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$265K
- Madrigal Pharmaceuticals$214K
- AbbVie$206K
- Gilead$182K
- Ipsen Biopharmaceuticals, Inc$166K
- Exelixis Inc.$164K
- plus $409K from 29 others
Across 97 payments — averaging $3440.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Intercept Pharmaceuticals, Inc.$175K
- Bausch Health US, LLC$59K
- Gilead$50K
- Intercept Pharma Europe Ltd.$44K
- AbbVie$5K
- Novo Nordisk AS$121
What the payments were for
- Consulting fees$234,46715%
- Speaking & faculty fees$1,196,45074%
- Travel & lodging$125,5558%
- Food & beverage$49,7533%
- Education$160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 271 | $265,134 |
| Madrigal Pharmaceuticals | 182 | $213,963 |
| AbbVie | 313 | $205,907 |
| Gilead | 282 | $181,573 |
| Ipsen Biopharmaceuticals, Inc | 85 | $165,801 |
| Exelixis Inc. | 187 | $164,486 |
| AstraZeneca | 112 | $96,202 |
| Intercept Pharmaceuticals, Inc. | 96 | $92,205 |
| Novo Nordisk | 30 | $50,520 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 46 | $29,624 |
| Shionogi Inc | 23 | $24,594 |
| Recordati_rare_diseases_inc. | 22 | $15,519 |
| Alnylam Pharmaceuticals Inc. | 12 | $13,948 |
| Boehringer Ingelheim | 6 | $13,742 |
| Genentech USA, Inc. | 29 | $12,518 |
| Dova Pharmaceuticals | 9 | $11,608 |
| E.r. Squibb & Sons, L.L.C. | 10 | $10,701 |
| Mirum Pharmaceuticals, Inc. | 25 | $9,821 |
| F. Hoffmann-la Roche AG | 1 | $7,260 |
| Merck | 9 | $5,584 |
| Bayer | 5 | $3,446 |
| Sirtex Medical Inc | 2 | $3,254 |
| Amgen | 7 | $3,200 |
| Genentech, Inc. | 2 | $2,389 |
| Boston Scientific | 7 | $2,311 |
| Beigene, Ltd. | 1 | $350 |
| Mallinckrodt Hospital Products Inc. | 3 | $153 |
| Johnson & Johnson | 8 | $119 |
| Eiger Biopharmaceuticals, Inc. | 1 | $104 |
| Ironwood Pharmaceuticals, Inc | 3 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $51 |
| Shire North American Group Inc | 2 | $32 |
| Ardelyx, Inc. | 2 | $31 |
| QOL Medical, LLC | 1 | $19 |
| Pfizer | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,606,241 in reported general payments places this provider in the 95th percentile of 657 gastroenterology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OcalivaObeticholic Acid | 36 | $357,188 |
| XifaxanRifaximin | 85 | $287,247 |
| EpclusaSofosbuvir/Velpatasvir | 11 | $269,136 |
| IqirvoElafibranor | 19 | $221,093 |
| VemlidyTenofovir Alafenamide | 87 | $123,455 |
| RezdiffraResmetirom | 25 | $96,977 |
| Ursodiol | 58 | $19,369 |
| Everolimus | 11 | $18,693 |
| Tacrolimus | 60 | $6,518 |
| Mycophenolate Mofetil | 35 | $3,902 |
| Entecavir | 13 | $2,644 |
| Spironolactone | 84 | $1,400 |
| Prednisone | 77 | $831 |
| Azathioprine | 41 | $754 |
| Eplerenone | 15 | $579 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa, Vemlidy | $181,573 | $392,59198 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $92,205 | $357,18836 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $29,624 | $287,24785 claims |
| Ipsen Biopharmaceuticals, IncIqirvo | $165,801 | $221,09319 claims |
| Madrigal PharmaceuticalsRezdiffra | $213,963 | $96,97725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 657 gastroenterology providers in Ohio.
Other gastroenterology in Cleveland
- Florian RiederCleveland$396K
- Stanley CohenCleveland$338K
- Taha QaziCleveland$307K
- Vu NguyenCleveland$145K
- Benjamin CohenCleveland$144K
- Imad AsaadCleveland$141K
- Ronnie FassCleveland$123K
- Amit BhattCleveland$118K
- Anjana PillaiCleveland$115K
- Amandeep SinghCleveland$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.